RELYSTEN
Pharmaceutical and biological preparations based on base editing, base modification, nucleobase editing, nucleobase modification, nucleic acid editing, gene editing, gene modification, gene modulation, gene therapy, genome editing, genome modification, cell therapy, cellular modification, and tissue modification for use in human therapeutics for the treatment of Sickle Cell Disease
Pending · March 27, 2026 · 99729369 ·